Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRX-341
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
GeRX-341 is a preclinical-stage oral gel formulation being developed by Gelteq for veterinary oncology applications. Utilizing Gelteq's proprietary ingestible gel platform, the formulation is designed to improve the oral delivery, bioavailability, and ease of administration of oncology therapeutics in animals, particularly addressing challenges associated with poor solubility and swallowing difficulties.
Beyond the preview
Go deeper on GeRX-341.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRX-341.